Beijing Friendship Hospital

A prospective, multicenter, single-blind, randomized, parallel-controlled trial evaluated the efficacy and safety of a new absorbable hemostatic gelatin matrix for intraoperative auxiliary hemostasis. Conducted from August 2020 to July 2021 across four Chinese hospitals, the study compared the Borayflo Haemostatic matrix with the Surgiflo Haemostatic matrix. Participants were randomly allocated to either group, with a focus on effective rates of hemostasis at 5 minutes post-application. The study adhered to the CONSORT guidelines and received ethical approval from each participating hospital's ethics committee.